Back

Systemic anti-inflammatory therapy and risk of major adverse cardiovascular events in patients with psoriasis: a population-based cohort study

30 August 2026 (12:15 - 12:45)
Organised by: Logo
Congress Presentation Part of: What raises your risk of cardiovascular disease? Epidemiology ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Yoav Elizur

The Chaim Sheba Medical Center, Tel Hashomer (Israel)

4 More presentations in this session

Presentation thumbnail
Monogenic familial hypercholesterolaemia confers excess premature cardiovascular risk beyond LDL-C: a family-lineage and LDL-C–matched analysis
Doctor J. Krefting (Munich, DE)
Abstract
Presentation thumbnail
Association of Cardiovascular-Kidney-Metabolic syndrome in young adulthood with subsequent major adverse cardiovascular events, all-cause mortality, and midlife Cardiovascular-Kidney -Metabolic stages
Doctor J. Wang (Shanghai, CN)
Abstract
Presentation thumbnail
Risk of in-hospital cardiovascular events according to type of respiratory viral infection: comparison between RSV, influenza and virus-negative patients
Doctor J. Perea (Buenos Aires, AR)
Abstract
Presentation thumbnail
Heterozygous ABCC6 variant carriers are not at a higher risk for cardiovascular disease events than noncarriers
Miss M. Haverkamp (Utrecht, NL)
Abstract

Access the full session

Session thumbnail
What raises your risk of cardiovascular disease?

The Event

Event poster

ESC Congress 2026

30 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Association of inflammatory disease and long-term outcomes among young adults with myocardial infarction: The Partners YOUNG-MI registry
29 August 2020
thumbnail
Congress Presentation
Longitudinal myocardial deformation and its improvement after treatment has an additive prognostic value to SCORE2 in psoriasis: a 4-year follow-up study
26 August 2023
thumbnail
Congress Presentation
Cardiovascular adverse events after CAR-T, BiTEs and TILs therapies: a systematic review and meta-analysis
21 June 2025
thumbnail
Congress Presentation
Meta-analysis assessing cardiovascular outcomes with febuxostat versus allopurinol for patients with gout
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources